Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan

RAS/BRAF mutations are the most remarkable oncogenic driver mutations in colorectal cancer (CRC) and play an important role in treatment selection. No data are available regarding the clinical and prognostic features of patients with detailed RAS/BRAF -mutant metastatic CRC (mCRC) in Japan. A total...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2021-05, Vol.21 (1), p.518-518, Article 518
Main Authors: Ikoma, Tatsuki, Shimokawa, Mototsugu, Kotaka, Masahito, Matsumoto, Toshihiko, Nagai, Hiroki, Boku, Shogen, Shibata, Nobuhiro, Yasui, Hisateru, Satake, Hironaga
Format: Article
Language:English
Subjects:
Cancer
Chemotherapy
Colorectal cancer
Colorectal carcinoma
Enrollments
Gene mutations
Genetic aspects
KRAS Exon2
KRAS non-Exon2
Medical prognosis
Metastases
Metastasis
Mutants
Mutation
NRAS
Oligonucleotides
Oncology, Experimental
Patients
Polymerase chain reaction
Prognosis
Survival
Tumors
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:RAS/BRAF mutations are the most remarkable oncogenic driver mutations in colorectal cancer (CRC) and play an important role in treatment selection. No data are available regarding the clinical and prognostic features of patients with detailed RAS/BRAF -mutant metastatic CRC (mCRC) in Japan. A total of 152 chemotherapy-naïve patients with mCRC were included in this study between August 2018 and July 2019. Tumor samples were collected, and RAS/BRAF status was investigated. RAS/BRAF status was examined using a MEBGEN RASKET-B kit and polymerase chain reaction reverse sequence-specific oligonucleotide method. RAS/BRAF mutations were detected in 54% of cases (KRAS codon 12, 26%; KRAS codon 13, 17%; KRAS non-Exon2, 5%; NRAS, 5%; and BRAF , 7%). BRAF -mutant CRC mainly existed in the right colon, whereas KRAS non-Exon2 and NRAS-mutant CRC was predominantly present in the left colon. KRAS non-Exon2 and NRAS-mutant CRC were associated with shorter survival time than RAS wild-type CRC (hazard ratio [HR], 2.26; 95% confidence interval [CI], 0.64-8.03; p = 0.19; HR, 2.42; 95% CI, 0.68-8.61; p = 0.16) and significantly shorter overall survival than KRAS Exon2-mutant CRC (HR, 3.88; 95% CI, 0.92-16.3; p = 0.04; HR, 4.80; 95% CI, 1.14-20.2; p = 0.02). In our multicenter study, the findings elucidated the clinical and prognostic features of patients with detailed RAS/BRAF -mutant mCRC in Japan.
ISSN:1471-2407
1471-2407
DOI:10.1186/s12885-021-08271-z